In 2013, a study, Immunomodulatory Effects of ResistAid™: A Randomized, Double-Blind, Placebo-Controlled, Multidose Study, evaluated the ability of a proprietary arabinogalactan extract from the larch tree (ResistAid™, Lonza Ltd., Basel, Switzerland) to change the immune response in healthy adults to a standardized antigenic challenge of tetanus and influenza vaccines in a dose-dependent manner compared to placebo. The study showed that at a dose of 1.5 g/day, the proprietary arabinogalactan extract significantly increased the IgG antibody response to tetanus vaccine compared to placebo. As it is flu season, Today’s Practitioner is revisiting the study and the subject with an interview with Bryan Rodriguez, Global Products Manager, of Lonza, makers of Resist Aid. Download the full study at the end of this article.
To gain access to this article and the rest of our extensive database of full-text articles, please register below or log in here.